GLP-1 RA therapy was associated with improved arteriovenous fistula outcomes in hemodialysis patients with end-stage kidney disease, including reduced thrombosis, stenosis, and revision rates.
Better dialysis accessGLP-1 drugs protected arteriovenous fistulas from failure in dialysis patients — potentially reducing the need for revision surgeries
What the researchers found
GLP-1 RA therapy associated with improved AVF outcomes: reduced thrombosis, stenosis, and revision rates in hemodialysis patients with ESKD.
Why it matters
AVF failure is a major problem in dialysis, requiring repeat surgeries and increasing infection risk. GLP-1 drugs could protect this crucial lifeline.
How the study worked
Retrospective study of hemodialysis patients comparing AVF outcomes in GLP-1 RA users vs non-users.
What this study cannot tell us
Retrospective. Small GLP-1 user population in ESKD. Cannot determine causation.
How to read the evidence
Retrospective study. Novel finding for dialysis vascular access protection.
When this study was published
Published in 2025.
The bigger picture
GLP-1 drugs protect blood vessels throughout the body — now including the critical dialysis access site.
Questions still open
- Should GLP-1 drugs be standard for all dialysis patients?
- What mechanism explains AVF protection — anti-inflammatory or direct vascular?
- Would GLP-1 drugs help other vascular access types (grafts)?
Common questions
Can GLP-1 drugs help my dialysis fistula?
Why would a diabetes drug protect a dialysis fistula?
Read the original research
Glucagon-like peptide-1 receptor agonist therapy is associated with improved outcomes of arteriovenous fistulae.
Journal of vascular surgery
Citation
Hsu, Joshua; Ho, Bryan; Sayed, Rahman; Patel, Nathan T P; Dardik, Alan. (2026). Glucagon-like peptide-1 receptor agonist therapy is associated with improved outcomes of arteriovenous fistulae.. Journal of vascular surgery. https://doi.org/10.1016/j.jvs.2026.02.003